



LakePharma 2018 Symposium New Frontiers in Biologics

Friday, October 5th, 2018
So. San Francisco Conference Center

Agenda

8:00 AM – 8:55 AM Breakfast and Registration

8:55 AM – 9:00 AM Welcome Remarks

Morning Session I

9:00 AM – 9:30 AM

- Jordon Wang, Ph.D., VP, Antibody Discovery, LakePharma
"LakePharma Antibody Center Update"

9:35 AM – 10:10 AM

- Deepak Srivastata, M.D., President, Gladstone Institutes
"Cardiac Development: Basis for Disease and Regeneration"

10:15 AM – 10:40 AM Morning Break in Exhibition Area

Morning Session II

10:45 AM – 11:20 AM

- Damien Bates, M.D., Ph.D., FRACS, MBA, Chief Medical Officer & Head of Research, SanBio
"Clinical Development of MSCs for Chronic Neurological Deficits – the SanBio Experience"

11:20 AM – 11:55 AM

- Prasun Mishra, Ph.D., Founder and CEO, Agility Pharmaceuticals
"Cell therapy: New Frontiers and New Challenges"

12:00 PM – 1:15 PM Lunch Break

12:40 PM – 1:10 PM Breakout Sessions: In Salons A – D

- Jaymee Davis, Cell Therapy Business Development Manager, Thermo Fisher
"Next Generation Cell & Gene Therapy Products: The Market, The Tools, The Future"
- Yasmina Abdiche, Ph.D., Chief Scientific Officer, Carterra
"Accelerating Biotherapeutic Discovery With High Throughput Array SPR"
- Paul Jurcys, SVP IP Management, Nanomolar
"List and License Technologies: Anticipate the Next Technological Breakthrough"

Afternoon Session I

1:15 PM – 1:20 PM

- Brief Remarks

1:20 PM – 1:50 PM

- Hua Tu, Ph.D., CEO, LakePharma
"Update on LakePharma"

1:55 PM – 2:30 PM

- Hong Tan, Ph.D., CEO, Probe Life
"BLI and Beyond"

2:30 PM – 3:00 PM Afternoon Break and Poster Session

Afternoon Session II

3:05 PM – 3:40 PM

- Steven Banerjee, Founder and CEO, Mekonos
"Point-of-Care Gene Therapies Using Silicon Chip Architecture"

3:45 PM – 4:20 PM

- Janette Phi, COO, Xcell Biosciences
"Control Phenotypic and Genotypic Profiles in Conjunction with Rapid Expansion of Immune Cells, Stem Cells and Tumor Organoids by Mimicking the Human Microenvironment"

- Closing Remarks and Raffle

4:30 PM – 5:30 PM Networking & Happy Hour



LakePharma 2018 Symposium New Frontiers in Biologics

Friday, October 5th, 2018
So. San Francisco Conference Center

Speaker & Presenter Biographies

Hua Tu, Ph.D., CEO

LakePharma

Dr. Hua Tu is the founder and CEO of LakePharma, the Protein Engineering CRO started in the San Francisco Bay Area. He received his academic training at State University of New York at Stony Brook and Cold Spring Harbor Laboratory. After starting his biotech career as a postdoctoral fellow at Tularik, he continued to work on drug development at Tularik and Amgen. His ongoing aspiration is to help bring efficiency and scale to the life science industry.

Deepak Srivastata, M.D., President

Gladstone Institutes

Deepak Srivastava, M.D., is the President of the Gladstone Institutes, Director of the Roddenberry Stem Cell Center at Gladstone, and is also a Professor at the University of California, San Francisco (UCSF) Medical Center. Dr. Srivastava received his B.S. from Rice University, M.D. from University of Texas, trained in pediatrics at UCSF, and in pediatric cardiology at Harvard Medical School. Dr. Srivastava's laboratory discovered genetic bases for cardiac defects and revealed complex signaling, transcriptional, and translational networks that regulate progenitor cells to adopt a cardiac cell fate and subsequently fashion a functioning heart. He has leveraged this knowledge to understand disease mechanisms using iPS cells and to reprogram fibroblasts directly into cardiomyocyte-like cells for regenerative purposes.

Janette Phi, COO

Xcell Biosciences

Janette is currently Chief Operations Officer at Xcell Biosciences. Prior to joining Xcell Bio, Ms. Phi was Chief Business Officer at IntelliCyt Corporation (a Sartorius Company). She has over 25 years of experience in the life sciences, coupled with extensive clinical experience. In addition to her leadership roles at IntelliCyt and Xcell Bio, Janette previously held senior management positions at ForteBio, Guava Technologies, AmCell and Becton Dickinson Biosciences. Janette holds a degree in Cell Biology from UC Berkeley and an MBA. .

Damient Bates, M.D., Ph.D., FRACS, MBA Chief Medical Officer and Head of Research

SanBio, Inc.

Dr. Bates is the Chief Medical Officer & Head of Research for SanBio, Inc. a stem cell company based in both Tokyo and Mountain View, California. Prior to his current position at SanBio, Dr. Bates has held senior executive & leadership roles in clinical development and medical affairs in multiple US based companies including Baxter, Organogenesis and Allergan. As Chief Medical Officer of Organogenesis, he successfully led the first BLA approval of an allogeneic cell based product in the US in 2012. Dr. Bates has also led the design and execution of over 20 IND, IDE and CTN studies across drugs, biologics and devices in the US and Asia and has had extensive regulatory interactions with the FDA, PMDA and EMA around the development and approval of cell based medicines. Dr. Bates received his medical degree from the University of Sydney, his PhD in Developmental Biology from the University of Melbourne, his Fellowship in Plastic & Reconstructive Surgery from the Royal Australasian College of Surgeons, and his MBA from the Wharton Business School.



LakePharma 2018 Symposium
New Frontiers in Biologics

Friday, October 5th, 2018
So. San Francisco Conference Center

Speaker & Presenter Biographies Cont.

Prasun Mishra, Ph.D., Founder and CEO

Agility Pharmaceuticals

Prasun Mishra is a scientist turned entrepreneur currently leading the scientific, strategic and business aspects of Agility Pharmaceuticals (Agility), based in San Francisco Bay Area, CA. He is also founding president and CEO of American Association for Precision Medicine (AAPM), a professional organization dedicated to advancing the field of precision medicine. He has collectively over 16 years of solid record of performance in big pharma, government, academia, start-up & healthcare settings that spans multiple therapeutic areas, including oncology, inflammation, fibrosis and aging. He is best known for discovering the role for noncoding RNA in drug resistance and pharmacogenomics. Moreover, his passion for drug development and precision medicine has led to identification of new drug targets, biomarkers, companion diagnostics, and mechanisms of action/resistance of both new and established drugs, which has facilitated development of rational drug combinations in the clinic.

Steven Banerjee, Ph.D., Founder and CEO

Mekonos

Steven invented the patent pending KAREL technology during his PhD research in mechanical engineering at the University of Canterbury. He is a former IBM Blue Fern Fellow, a MacDiarmid Commercial Fellow and was selected as one of the 100 Leaders of Tomorrow at the 41st St.Gallen Symposium in 2011 in Switzerland. He earned his Engineering degree from the University of Canterbury. Steven was originally supposed to join the Stanford Genome Technology Center as a Visiting Scholar before he pivoted to focus full-time at Mekonos. He is currently a Visiting Scholar at UC Berkeley under the Global Founders Program.

Jordon Wang, Ph.D., VP, Antibody Discovery

LakePharma

Jordon Wang, Ph.D., is the Vice President of Antibody Discovery at LakePharma. He has led multiple groups, internal and external, that form the Antibody Center to serve our clients. Prior to LakePharma, Dr. Wang guided the early discovery efforts and research alliance with Pfizer at Crown Biosciences. Dr. Wang received a Ph.D. in Cancer Biology and B.S. in Biological Sciences from Stanford University.

Hong Tan, Ph.D., CEO

Probe Life

Hong began his entrepreneurial career in 2000 when he founded Wave Crossing, a fiber optics company that developed a self-focus lens technology widely used in the optic fiber networks. In 2001, Hong founded FortéBio, where he led the creation of the Bio-layer Interferometry technology. Before starting his entrepreneurial endeavor, he worked for several data storage companies, including Iomega, Seagate, and Maxtor. Hong was responsible for the control system for the High Energy Imaging Device, a NASA space telescope project. He received Ph.D. and MSEE from Auburn University, BSEE from Xi'an Jiao Tong University, and EMBA from Cheung Kong Graduate School of Business.



LakePharma 2018 Symposium
New Frontiers in Biologics

Friday, October 5th, 2018
So. San Francisco Conference Center

Poster Session

2:20 PM – 3:00 PM

“A Novel T-Cell Engaging Bispecific Antibody Platform: Maximizing Tumor Cell Cytotoxicity While Minimizing Cytokine Release”

Katherine Harris, Nathan Trinklein, Shelley Force Aldred, Ute Schellenberger, Brian Avanzino, Aarti Balasubramani, Laura Davison, Keshav Narayan, Heather Ogana, Starlynn Clarke, Kevin Dang, Duy Pham, Payal Pratap, Harshad Ugamraj, Omid Vafa, and Wim VanSchooten

TeneoBio

“Identification Of An Antibody Pair From The Serum Of An Immunized Rabbit”

Natalie Castellana

Digital Proteomics

“Cancer Therapy with CAR-T Cell Constructs of Humanized RP215 and GHR106 Monoclonal Antibodies”

Dr. G Lee

Vancouver Biotech Ltd.

“The Development of a Next Generation Antibody Drug Conjugate”

Bethanne Deuel

MabPlex

“A Novel Platform For Probing Low Affinity Protein Interactions”

Kalidip Choudhury

MagArray

“Functional Antibodies for GPCRs”

Brett Robison, Stephanie Lopez, C. Gustavo Pesce and Richard Yu

Abalone Bio

“Discovery and Characterization of Potent TIGIT- Specific Antibodies Derived from Very Diverse Phage Display Libraries”

Raphael Levy

LakePharma, Inc.



LakePharma 2018 Symposium New Frontiers in Biologics

Friday, October 5th, 2018
So. San Francisco Conference Center

Online Registration:

Open through Wednesday, October 3, 2018

www.lakepharma.com/symposium

Symposium Organizing Committee:

Hua Tu, Ph.D. CEO, LakePharma, Inc.

Norman Garceau, Ph.D. VP, Technology, LakePharma, Inc.

Yuko Terasawa, Ph.D. SVP, Corporate Development, Nanomolar, Inc.

Announcement:

Email symposium@lakepharma.com to submit abstracts for poster session (subject to availability)

Symposium Sponsors and Exhibitors:

